Yuhan Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Wook-Je Cho

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Is Yuhan (KRX:000100) Using Too Much Debt?

Oct 08

Estimating The Intrinsic Value Of Yuhan Corporation (KRX:000100)

Sep 16

Subdued Growth No Barrier To Yuhan Corporation (KRX:000100) With Shares Advancing 41%

Aug 28

Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Jul 01

Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 13

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

May 26

Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

May 13

Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Mar 11

Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

May 01

Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Apr 16

Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Mar 15

Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Feb 25

Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Feb 10

Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

Jan 28

The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

Jan 13

Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Nov 20

CEO

Wook-Je Cho (69 yo)

no data

Görev süresi

Mr. Wook-Je Cho is the President, CEO & Executive Director at Yuhan Corporation. He was Head of the Planning and Management Division at Yuhan Corporation and served as its Head of Pharmaceutical Business C...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Wook-Je Cho	President	no data	Veri yok	0.025% ₩ 2.7b
Yeul-Hong Kim	Executive Director	less than a year	Veri yok	0.0061% ₩ 650.9m
Jung-Hee Lee	Non-Executive Director	no data	Veri yok	0.078% ₩ 8.2b
Sung Gil Chi	Independent Outside Director	no data	Veri yok	Veri yok
Dong-Jin Park	Independent Outside Director	no data	Veri yok	0.0027% ₩ 286.1m
Jun-Cheol Kim	Independent Outside Director	3.8yrs	Veri yok	Veri yok
Young-Jae Shin	Independent Outside Director	3.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

69yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: A000100 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Yuhan Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Yuhan Corporation, Annual General Meeting, Mar 19, 2021

Recent updates

Is Yuhan (KRX:000100) Using Too Much Debt?

Price target increased by 8.1% to ₩110,188

Price target increased by 7.9% to ₩108,412

Investor sentiment improves as stock rises 17%

Estimating The Intrinsic Value Of Yuhan Corporation (KRX:000100)

Investor sentiment improves as stock rises 44%

Subdued Growth No Barrier To Yuhan Corporation (KRX:000100) With Shares Advancing 41%

Price target increased by 7.1% to ₩99,222

Investor sentiment deteriorates as stock falls 15%

Now 20% undervalued

Investor sentiment improves as stock rises 15%

Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Investor sentiment improves as stock rises 19%

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

Consensus revenue estimates increase by 28%

Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

Now 22% overvalued after recent price rise

Full year 2023 earnings released: EPS: ₩1,815 (vs ₩1,267 in FY 2022)

Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Investor sentiment improves as stock rises 18%

Insufficient new directors

Now 21% undervalued

Upcoming dividend of ₩381 per share at 0.6% yield

Consensus EPS estimates increase by 37%, revenue downgraded

Investor sentiment deteriorates as stock falls 23%

Now 24% undervalued

Price target increased by 7.8% to ₩80,222

First quarter 2023 earnings released: EPS: ₩311 (vs ₩222 in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

Upcoming dividend of ₩381 per share

Consensus EPS estimates fall by 11%

Now 20% undervalued

Full year 2021 earnings: EPS and revenues miss analyst expectations

Yuhan Corporation (KOSE:A000100) announces an Equity Buyback for KRW 20,000 million worth of its shares.

Upcoming dividend of ₩381 per share

Third quarter 2021 earnings released: EPS ₩470 (vs ₩464 in 3Q 2020)

First quarter 2021 earnings released: EPS ₩315 (vs ₩1,768 in 1Q 2020)

Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

Consensus forecasts updated

Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Full year 2020 earnings released: EPS ₩2,943 (vs ₩610 in FY 2019)

New 90-day low: ₩60,700

Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Yuhan Corporation, Annual General Meeting, Mar 19, 2021

Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

New 90-day high: ₩75,100

Is Yuhan Corporation (KRX:000100) Popular Amongst Institutions?

New 90-day high: ₩75,100

Estimating The Fair Value Of Yuhan Corporation (KRX:000100)

New 90-day high: ₩72,300

Is Yuhan Corporation's (KRX:000100) 0.6% Dividend Worth Your Time?

Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Price target raised to ₩72,704

Price target raised to ₩67,579

Yuhan Corporation and Sorrento Therapeutics, Inc. Announces Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

New 90-day high: ₩72,000

Price target raised to ₩63,148

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş